Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK3 M511I |
Therapy | Dexamethasone + Tofacitinib |
Indication/Tumor Type | T-cell acute lymphoblastic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 M511I | T-cell acute lymphoblastic leukemia | sensitive | Dexamethasone + Tofacitinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Xeljanx (tofacitinib) and Adexone (dexamethasone) combination treatment increased apoptosis and synergistically reduced viability of a patient-derived T-cell acute lymphoblastic leukemia cell line harboring JAK3 M511I in culture and resulted in reduced leukemic burden in a patient-derived xenograft (PDX) model compared to either drug alone (PMID: 35411095). | 35411095 |
PubMed Id | Reference Title | Details |
---|---|---|
(35411095) | JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. | Full reference... |